Slide 1: Early Warning and Enhanced Detection for Heart Disease
Early Warning and Enhanced Detection for Heart Disease ASX:EIQ Company Presentation: 23 May 2024
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This presentation has been prepared by ECHOIQ LIMITED <EIQ=. This document jurisdiction of the United States, and may not be offered or sold in the United contains background information about EIQ current at the date of this States to any person without bein
Slide 3: Corporate Snapshot
Corporate Snapshot 495,154,376 SHAREHOLDER BREAKDOWN Shares on issue 49% 51% A$0.135 Board of Directors Other & Top 20 Shareholders Share Price (22.05.2024) BOARD OF DIRECTORS A$66.8M Market Capitalisation $385,000 Average monthly cash burn adjusted to incorp. R+D rebate (past 12 mos) Andew Grover A
Slide 4: The Problem
The Problem Diseases of the heart are the leading cause of death worldwide. However, even though treatment options are improving, accurate diagnosis remains complex. And delayed or missed diagnosis and treatment costs lives. 30% 1 in 2 2 yrs (1) (2) (3) of all deaths worldwide people with heart valv
Slide 5: Challenges in Diagnosis
Challenges in Diagnosis Trans-Thoracic Diagnostic EchoCardiogram Complexity > Images of the heart captured using > Cardiologists are often looking for ultrasound (soundwaves) multiple conditions at once > Most widely used tool in the > Many conditions share similar diagnosis of structural heart dise
Slide 6: Harnesses the power of artificial intelligence and cardiac big data
harnesses the power of artificial intelligence and exclusive access to world-leading cardiac big data to help healthcare profesionals obtain earlier and more accurate diagnoses for structural heart disease.
Slide 7: Our Competitive MOAT
BACKED BY CLINICALLY Our CARDIAC BIG DATA > Exclusive AI access to National VALIDATED > US study demonstrated 100% Competitive Echo Database of Australia accuracy in detection of AHA (NEDA) echo measurement defined severe aortic stenosis data (world’s largest) > Australian study showed MOAT signific
Slide 8: Focus on Aortic Stenosis
Focus on Aortic Stenosis 1.5m $10bn Aortic Stenosis is a common form of heart valve disease. (5) (6) It’s known to be fatal when left untreated, but can be hard to diagnose people have AS direct US healthcare accurately. in the USA alone costs now The focus of Echo IQ’s early research and developmen
Slide 9: FDA Application
-AS FDA APPLICATION MAY 7, 2024 EchoSolv removes the labour intensiveness, user-dependency and unconscious bias in diagnosis which can lead to greater accuracy compared to traditional methods. Patient triage Real-time Rapid AI View Guideline on-the-go alerts results Phenotyper 360 detection Assessme
Slide 10: Case Study: EchoSolv-AS
Case Study: EchoSolv-AS 550 Location: St. Vincent’s Sydney + Melbourne Population: 9,189 patient’s echocardiograms Study Funding: Edwards Lifesciences Total high-risk 376 cases comprising: Key Findings: 376 (Guideline defined) Where human-only diagnosis identified 218 patients with severe AS, + Echo
Slide 11: US Exposure - June 2024
US Exposure - June 2024 Independent presentation of findings from recent EchoSolv-AS pilot with major US hospital group Results to include data on performace of EchoSolv vs human-only diagnosis from US sites, covering more than 200,000 sets of patient records Third-party, independent presentation to
Slide 12: Product Development: Heart Failure
Product Development: Heart Failure Heart Failure is a complex life-threatening syndrome that leads to ill-health, risk of death and high costs of care. It affects more than 64m people worldwide. It is the leading (10) cause of hospitalisation for the over 65 (11), and the number 1 cause of re-hospit
Slide 13: Heart Failure
Heart Failure Current diagnostic tools only rule in or rule out the presence of No HF Heart Failure in 40% of cases sent HF for echocardiographic evaluation. (16) No Diagnosis More than half of all patient echocardiograms generate no clear diagnosis.
Slide 14: Heart Failure
Heart Failure Echo IQ’s novel AI algorithm HF generates a risk score for ALL HIGHEST RISK patients sent for screening vs fewer than 50% today. This could double the number of HF LOWEST patients being effectively treated RISK for heart failure.
Slide 15: Heart Failure: Pathway to Clearance
Heart Failure: Pathway to Clearance Clinical Studies (A) FDA Pre-Submission Clinical Study (B) FDA 510(k) FDA 510(k) Operational Study Design + Clinical Application Clearance Characteristics Approach Validation St. Vincent’s USA Site Underway MONTHS: 3 6 9 12 Timeframes Updated FDA guidance (as of M
Slide 16: Commercialisation - Reimbursement
Commercialisation - Reimbursement US Insurance Coverage Fee-per-use US health insurance is estimated to cover approximately 90%(17) of Americans, either Reimbursement through private of public programs. CMS Codes for insured patients CMS Codes Hospitals Echo Labs ACO’s Securing CMS codes for Echo IQ
Slide 17: Commercialisation - Licensing
Commercialisation - Licensing Licensing Fee-per-partnership or PPPM Echo IQ has engaged with a number of prospective licensing partnerships with a Licensing view to leverage EchoSolv to help unlock additional market share for their products Partnership pricing for therapeutics providers and services
Slide 18: Investment Highlights
Investment Highlights 1 Exclusive access to NEDA - world leading cardiac big data 2 FDA application for aortic stenosis submitted - response due early Aug 824 3 Strong product development with rapid delivery plan for heart failure solution 4 Significant commercial opportunity to impact world9s bigge
Slide 19: Scientific Advisory Board
Scientific Advisory Board > Comprises a team of globally recognised experts in cardiovascular medicine, echocardiography, sonography, applied artificial intelligence and public health > More than 1,200 peer-reviewed publications > Former Presidents and Chairs, Am. College Cardiology and Am. Soc. Ech
Slide 20: References
References (1) https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2) https://www.baker.edu.au/impact/advocacy/valve-disease (3) https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Support/Risk-Communications/5-Explaining-Risk-to-Pati
Slide 21: ASX:EIQ www.echoiq.ai
Echo iQ Ai with heert ASX:EIQ www.echoiq.ai